Political Contributions

Given recent events, the Amgen PAC is temporarily suspending political action committee disbursements pending a review of future contributions.

Amgen looks forward to working with President-elect Biden and lawmakers in both parties to ensure that patients have affordable access to medicines and that our society continues to support the discovery of innovative new medicines.

U.S. Government Affairs

Amgen recognizes the importance of sound public policy in supporting our mission of serving patients by helping to ensure that patients have access to needed therapies.  It is appropriate for companies like Amgen to participate constructively in the United States political process to help inform debate around healthcare policy including ideas like biotechnology innovation, patient access to new and existing treatments and sound science.

U.S. Government Affairs (USGA) engages in the public policy debate primarily by communicating information and engaging with elected officials and other policy makers in Washington, D.C. and throughout the country. Amgen employs internal and outside experts to assist our advocacy and policy analysis activities.

Amgen has strict internal policies that oversee interactions between Amgen staff and government officials. Amgen and other entities are required to register and report federal lobbying activities to the Clerk of the U.S. House of Representatives and the Secretary of the U.S. Senate. All relevant Amgen staff and outside firms are also required to comply with the Lobbying Disclosure Act (LDA) and Honest Leadership and Open Government Act. (You can view Amgen's lobbying disclosure data at this address by selecting "registrant name" and "submit." Then enter "Amgen Inc" in the registrant name box and "submit.") These reported expenditures include the portion of Amgen's trade association dues used for lobbying.

Additional lobby disclosure rules often apply at the state and sometimes local levels, and Amgen has implemented internal policies regarding compliance with all applicable laws. The Corporate Responsibility and Compliance Committee of the Amgen Board of Directors has oversight of Amgen's USGA activities.

Amgen posts, on an annual basis, a list of all states where we file lobby reports and, to the extent available, either links to the reports filed with each state or links to state websites where such information can be found. Our most current report containing such information can be found here .

Political Contributions

Amgen participates in the political process by making contributions to federal and state political candidates and committees through our employee-funded PAC. Elected officials throughout the country make decisions on public policy issues impacting the biotechnology industry and the patients we serve.

The Corporate Responsibility and Compliance Committee also annually reviews Amgen's policies, practices, and overall philosophy for making political contributions. Designated Amgen senior managers oversee and approve all political contributions. Contributions are also audited by a third-party firm on a regular basis. Political contributions are made with Amgen’s best interests in mind and without regard for the personal political preferences of Amgen’s Board Members, executives or lobbyists.

The Amgen PAC

Although federal law generally prohibits corporations from making direct contributions in federal elections, a corporation may administer a PAC for its executives and administrative personnel. The Amgen PAC provides eligible U.S. staff an opportunity to support federal and state candidates who share Amgen's commitment to serving patients.

The Amgen PAC is funded solely by voluntary donations from eligible employees. The Amgen PAC Board (the Board) is comprised of Amgen staff representing various functions. The Board reviews a two-year PAC disbursements budget, consistent with federal election cycles, to ensure compliance with applicable laws.

Amgen is committed to conducting the PAC in accordance with all federal laws and regulations that govern activities of political action committees.

All PAC disbursements are publicly disclosed on a monthly basis and available on the website of the Federal Election Commission at www.fec.gov , and on a semi-annual basis via the disclosure reports below. Amgen also provides reports, as required, to certain state agencies and conducts an outside financial audit through a third-party firm at the close of each two-year election cycle.

Corporate Political Spending

While generally impermissible at the federal level, direct corporate political contributions can be made in some states to candidates running for state or local elected offices. Under certain circumstances, Amgen may also contribute to other state-level political committees. Amgen is committed to complying with all applicable laws, rules and regulations that govern such contributions.

Amgen supports state candidates who share the company's perspective on public policies that impact our ability to innovate and serve patients.

Since 2007, corporate political contributions have been disclosed on a semi-annual basis via the reports posted below.

Transparency Around Political Contributions

To improve access to information about Amgen's corporate political contributions in the United States, Amgen posts, on a semi-annual basis, our contributions categorized by state, candidate, and amount.

At this time, Amgen has not made federal Independent Expenditures (IEs) on behalf of candidates running for federal office under the 2010 Supreme Court decision in Citizens United.

Reports containing our political contributions can be found at the following links:

Memberships

In addition to direct political contributions, Amgen also maintains memberships in trade associations that report lobbying activity to the U.S. government. Amgen is committed to supporting trade associations that champion scientific innovation and patient access to new and existing therapies. A table that identifies each U.S. trade association that received at least $50,000 in dues payments from Amgen during 2019 and the portion of those payments identified by the trade association as being used for lobbying expenditures is listed below.

Organization

2019 $ Toward Lobbying

Quarter Paid 

Biotechnology Innovation Organization (BIO)

$125,400

Q4

California Life Sciences Association (CLSA)

$59,280

Q1, Q4

PhRMA

$2,092,020

Q1, Q3

US Chamber of Commerce

$125,000

Q3

Healthcare Leadership Council

$110,000

Q4

International Government Affairs

Outside the United States, rules governing interactions with policy makers vary by country. Amgen implemented internal policies regarding compliance with all applicable laws and regulations in countries where relevant interactions with policy makers occur, including the U.S. Foreign Corrupt Practices Act (FCPA).